Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

MALT LYMPHOMA Clinical Trial

Official title:
Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Status Completed

Clinical Trial Summary

The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.

Primary endpoint:

- Event-free-survival (EFS) (failure or death from any cause) for all patients.

Secondary endpoints:

- Complete and partial remission rates for all patients

- Response duration (time to relapse or progression) for responder patients

- Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients

- Overall survival for all patients

- Acute and long-term toxicity

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01015248
Study type	Interventional
Source	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Contact
Status	Completed
Phase	Phase 2
Start date	May 2009
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05003141` - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Phase 1
Completed	`NCT00373646` - Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients	Phase 2
Completed	`NCT00201422` - Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma	N/A
Unknown status	`NCT00923663` - Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type	Phase 2
Completed	`NCT00783367` - Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas	Phase 2
Active, not recruiting	`NCT01808599` - Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma	Phase 2
Completed	`NCT00117156` - Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT05544019` - Study of SGR-1505 in Mature B-Cell Neoplasms	Phase 1
Completed	`NCT00373906` - Velcade in MALT Lymphoma Patients	Phase 2